Drug intelligence / Profile preview

lamivudine + stavudine

Development stage
Phase 3
Lead developer
Cipla
Modality
Small Molecules
Administration
Oral
01

Overview

Lamivir-S is a fixed-dose combination antiretroviral medication containing lamivudine (3TC) and stavudine (d4T), both of which are nucleoside reverse transcriptase inhibitors (NRTIs). Developed by Cipla and evaluated in clinical trials such as the CHAPAS-1 pediatric HIV trial in Zambia (supported by the Medical Research Council), Lamivir-S is used in the treatment of human immunodeficiency virus (HIV) infection. It works by inhibiting the viral reverse transcriptase enzyme, thereby blocking the replication of HIV-1. In pediatric settings, it has been utilized as part of a dose-escalation strategy alongside nevirapine to minimize early side effects like rash while maintaining therapeutic levels of the nucleoside backbone.

Brand names
Lamivir-SLamivir S
Other names
lamivudine/stavudinestavudine/lamivudined4T/3TC3TC/d4T
02

Targets

POLA1 (DNA polymerase alpha)POLB (DNA polymerase beta)POLG (Mitochondrial DNA polymerase gamma)Human immunodeficiency virus type 1 reverse transcriptaseHIV-2 reverse transcriptaseHBV Pol (Hepatitis B virus polymerase)

Beyond the preview

Go deeper on lamivudine + stavudine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lamivudine + stavudine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call